Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916630 · ClinicalTrials.gov registry record · Phase 1
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
A Phase 1 study of Central Nervous System Lymphoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT00916630: Completed Phase 1 study of Central Nervous System Lymphoma, sponsored by Massachusetts General Hospital.
NCT00916630 is a Phase 1 study of Central Nervous System Lymphoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 18 participants, below the 104-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00916630, a Phase 1 study of Central Nervous System Lymphoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to determine the safety of the study drug pemetrexed, and the highest dose of this drug that can be given to people safely. Another goal of this research study is to gain information about how the body handles pemetrexed and how pemetrexed may work to treat the participant's lymphoma in the nervous system. Pemetrexed (also known as Alimta) has been approved by the FDA for the treatment of some lung cancers and has been shown to be effective in laboratory studies. Information from these studies suggests that pemetrexed may help to treat patients with either primary or secondary central nervous system lymphoma.
Conditions Studied
Interventions
- DRUG pemetrexed
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
What the finished NCT00916630 record still lists
NCT00916630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 104-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which pemetrexed is the first listed.
NCT00916630 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00916630 about?
NCT00916630 is a clinical study titled "Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)". The purpose of this research study is to determine the safety of the study drug pemetrexed, and the highest dose of this drug that can be given to people safely. Another goal of this research study is to gain information about how the body handles pemetrexed and how pemetrexed may work to treat the ...
What is the current status of trial NCT00916630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-01. Estimated completion is 2015-09.
What conditions does trial NCT00916630 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma.
What interventions are being tested in trial NCT00916630?
The interventions under investigation include: pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00916630?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00916630 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00916630's enrollment target sits among peer trials
18 12th of 14 higher than 3 of 14 other Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Acalabrutinib in CNSL
ACTIVE NOT RECRUITING · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia